Research & Development: Page 32
-
PharmaVoice Team/PharmaVoice
ProfilePharmaVoice 100 Who's on the List – By Category
Who’s on the List — 2021 Indexed by Category Commanders & Chiefs Dr. Sam Agresta Foghorn Therapeutics Alisha Alaimo Biogen Shideh Bina Insigniam Dr. Norbert Bischofberger Kronos Bio Dr. James Kyle Bryan IQVIA Biotech Victor Bultó Novartis Pharmaceuticals Dr. Tony ...
By PharmaVoice Team • Aug. 1, 2021 -
PharmaVoice Team/PharmaVoice
Profile
Clinical Experts
These clinical development experts are redefining clinical operations to increase efficiencies, reduce costs and timelines, and improve the safety profiles of bringing new medicines to patients. Unwavering determination to further clinical research Igniting change by… ensuring cross...
By PharmaVoice Team • Aug. 1, 2021 -
Explore the Trendline➔
Stock via Getty Images
TrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Letter from the Editor
The clinical trial horizon The rise of decentralized clinical trials, otherwise known as DCTs, is the hottest topic in the clinical research arena at the moment, and appropriately so. The global pandemic exposed significant cracks in the structure of how clinical trials have been conducted for de...
By Taren Grom • June 1, 2021 -
PharmaVoice Team/PharmaVoice
SHOWCASE: Clinical Trial Solutions: The Changing Face of Clinical Trial Solutions
Clinical trials have undergone significant change over the past year amid concerns over patient safety during the pandemic. According to a survey across biopharmaceutical companies, medical devices companies and clinical research organizations, 76% have sped up the move to virtual in the wake of ...
By PharmaVoice Team • June 1, 2021 -
PharmaVoice Team/PharmaVoice
Meeting the Demands of Today to Create the Treatments of Tomorrow
In our rapidly evolving clinical research industry, there’s never been a more important time to ensure you’re getting the most out of your central laboratory services. This is especially true in the face of the challenges brought about by the COVID-19 pandemic. While the landscape of clinical res...
By Tom Mueller • June 1, 2021 -
PharmaVoice Team/PharmaVoice
Lessons Learned from COVID-19
Why CROs Must Continue Modeling Support and Compassion to Clinical Sites When the COVID-19 pandemic hit in March 2020, a range of emotions followed, including shock and uncertainty. However, what we began to see was an increase in kindness and compassion both at home and at work. Faced with the c...
By Sheri Madrid • June 1, 2021 -
PharmaVoice Team/PharmaVoice
The Benefits of Flexible, Decentralized Trial Designs — And How to Make Them Happen
Clinical trial managers have used digital technology for several years to some degree. Now, because of the pandemic, digital technology has become a proven and valuable necessity. However, for all the benefits of bring your own device (BYOD), electronic patient-reported outcomes (ePRO), and direc...
By Jonathan Andrus • June 1, 2021 -
PharmaVoice Team/PharmaVoice
Seven Secrets to Patient Experience Breakthroughs
The principles of behavioral science can be used to keep participants engaged, adherent to the protocol, and proud of the contributions to curing disease. Consumer industries have invested millions in improving “customer experience" — how consumers feel or perceive every interaction with a compan...
By Kyle Hogan • June 1, 2021 -
PharmaVoice Team/PharmaVoice
Decentralization of Clinical Trials: Taking Into Account All Stakeholder Perspectives
At first, the COVID-19 pandemic threatened clinical research, with patients struggling to get to sites, hospitals becoming overloaded, and screening criteria becoming increasingly muddled due to widely circulating symptoms. However, the industry rallied to rapidly adapt and enable decentralizatio...
By Matthew McCarty • June 1, 2021 -
PharmaVoice Team/PharmaVoice
Data-Driven Outreach Drives Rapid Recruiting
The pandemic has accomplished something that the pharma industry has been trying to achieve for years: it got consumers excited about clinical research. The rush to develop vaccines and 24/7 coverage of the virus’ spread captivated audiences and made all populations more aware of trial participat...
By Mark Brown • June 1, 2021 -
PharmaVoice Team/PharmaVoice
Widening the Lens: From Patient Engagement to Community Engagement
To truly engage patients, we must incorporate their community support systems No patient travels through their health journey alone. To be patient-centric, and fully engage patients in clinical research, expanding our approach to be inclusive of the broader communities that support them is impera...
By Alycia James • June 1, 2021 -
PharmaVoice Team/PharmaVoice
AI in Clinical Trials: An Incredible Voyage
The 19th century English naturalist and seafarer Charles Darwin once said: “It is not the strongest of the species that survive, nor the most intelligent, but the one most responsive to change." He knew a thing or two about evolution. So does the life-sciences industry — especially after last yea...
By Jonathan Burr • June 1, 2021 -
PharmaVoice Team/PharmaVoice
Fulfilling the Promise of Wearables in Clinical Trials
Wearable sensors have the power to transform clinical trials and, indeed, medicine in general, by replacing sporadic, often subjective health measures with continuous, objective ones. Instead of doctors asking their patients during occasional visits whether they have been sleeping well or been ac...
By Geoffrey Gill • June 1, 2021 -
PharmaVoice Team/PharmaVoice
Decentralized Trials: Moving Beyond One-Size-Fits-All
Suppose there’s a problem with your car’s suspension, you pull up to a service station, and the mechanic starts talking about replacing the engine and wheels. The scenario sounds comical, but it captures what could happen if a hasty, soup-to-nuts research approach is misapplied to decentralized c...
By Noolie Gregory • June 1, 2021 -
PharmaVoice Team/PharmaVoice
The Financial Benefits of Incorporating Decentralized Clinical Trial (DCT) Approaches
Clinical research trials are expensive to conduct and continue to rise in cost. Studies by Tufts and JAMA in recent years calculate the average cost to bring a drug to market steadily increasing to more than a billion U.S. dollars1. These rising research costs restrict R&D budgets for drug an...
By John Reites • June 1, 2021 -
PharmaVoice Team/PharmaVoice
Collaborations Across the Ecosystem
Over the past couple of years, there has been an increase in the number of collaborations designed to accelerate progress to solve R&D and patient challenges. Daiichi Sankyo and AstraZeneca Tackle Cancer Ken Takeshita, M.D., Global Head of Research and Development Daiichi Sankyo Cristian Mass...
By Taren Grom • June 1, 2021 -
PharmaVoice Team/PharmaVoice
Artificial Intelligence
Iktos Partners with Pfizer for AI-based Drug Design Project Trend Watch: COVID-19, Parkinson’s, Alzheimer’s All Benefiting from AI Platforms Iktos, an AI-based chemical research solution provider, and Pfizer are creating a design model for the pharma company’s selective small molecule discovery p...
By PharmaVoice Team • April 1, 2021 -
PharmaVoice Team/PharmaVoice
Trend Tracking
The industry is moving fast, and we asked our community of PharmaVOICE 100 inspired leaders to weigh in on their top priorities for the remainder of 2021 as they prepare for the next normal as well as the leadership skills that got them through the pandemic. Tammy Guld Global Head Multi-TA Projec...
By PharmaVoice Team • April 1, 2021 -
PharmaVoice Team/PharmaVoice
Decentralized Clinical Trials: The Way Forward
COVID-19 prompted the need for the industry to address patient needs in the clinical trial space, and companies along the drug development paradigm pivoted successfully to the benefit of patients. Necessity is the mother of invention, and over the past 12 to 18 months because of the limitations n...
By Taren Grom • March 1, 2021 -
PharmaVoice Team/PharmaVoice
SHOWCASE: Real-World Evidence: Realizing the Benefits of RWE
The real-world evidence (RWE) market has grown significantly in recent years, supported by a favorable regulatory environment. Increasingly, companies recognize that real-world evidence (RWE) presents an opportunity to improve efficiency and innovation. One of the biggest challenges for pharma co...
By PharmaVoice Team • March 1, 2021 -
PharmaVoice Team/PharmaVoice
Four Key Considerations When Using Real-World Data in Drug Development and Regulatory Submissions
Interest in using real-world data (RWD) in drug development and regulatory submissions has grown substantially over the past several years. This development can largely be attributed to passage of the 21st Century Cures Act, which mandated that FDA establish a program to evaluate the use of real-...
By Scott Swain • March 1, 2021 -
PharmaVoice Team/PharmaVoice
Leveraging RWE to Enhance Experiences Across the Patient Journey
In a tech-driven healthcare ecosystem in which patients are engaged consumers, product value is contingent on treatment outcomes and patient success. With digital tools and resources at their fingertips, today’s patient is empowered to make informed treatment decisions; and physicians need enhanc...
By Melissa Thompson • March 1, 2021 -
PharmaVoice Team/PharmaVoice
Modernizing Oncology Approvals
Using real world evidence to bolster oncology accelerated approvals and label extensions Regulators are increasingly leveraging real world evidence (RWE) to inform their understanding of the benefits and risks of using targeted therapies in patients who are treated as part of routine clinical car...
By Jennifer Christian • March 1, 2021 -
PharmaVoice Team/PharmaVoice
Shot in the Arm: COVID-19 Boost to RWD
Times Have Changed It’s early 2021 in the Northeast and a major snowstorm has just been announced. Schools will be closed for the next two days. Kids will be home and likely, quite happy to be off from school. Under normal circumstances, parents would be home too, trying to work and probably atte...
By Iyiola Obayomi • March 1, 2021 -
PharmaVoice Team/PharmaVoice
The RWE Evolution
With so much attention being focused on real-world evidence (RWE) and real-world data (RWD), it would be easy to assume that this critical area of drug development is revolutionary. But, in fact, RWE has been around for decades and what the industry is currently experiencing is an evolution of pr...
By David Brown • March 1, 2021
Previous
